Ofatumumab, a human anti-CD20 monoclonal antibody

Bibliography

• Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67(3):1270-81
   PubMed Web of Science ®Google Scholar
• Ries LAG, Young JL, Keel GE, SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics: National Cancer Institute, SEER Program, NIH Publication. Number 07-6215, Bethesda, MD, 2007
   Google Scholar
• Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother 2006;7(12):1641-51
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas V.2.2007. Available from: www.nccn.org
   Google Scholar
• Cheson BD, Bennett JM, Grever M, National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990-7
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A, Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2008;112(11):325
   Google Scholar
• Robak T, Moiseev S, Dmoszynska A, Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized Phase III REACH trial. ASH Annual Meeting Abstracts. Blood 2008;112(11):lba-1
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III Trial on behalf of an international group of investigators and the German CLL Study Group. ASH Annual Meeting Proceedings. Blood 2009;114:535
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Kontoyiannis D, Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43(9):1755-62
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Lerner S, The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48(10):1931-9
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22(11):2048-53
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48(12):2412-7
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U, High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93(3):475-6
   PubMed Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125(4):1678-85
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
   PubMedGoogle Scholar
• D'Arena G, Musto P, Cascavilla N, Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000;64(4):275-81
   PubMed Web of Science ®Google Scholar
• Rossmann ED, Lundin J, Lenkei R, Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2(5):300-6
   PubMedGoogle Scholar
• Kosmas C, Stamatopoulos K, Stavroyianni N, Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 2002;16(10):2004-15
   PubMed Web of Science ®Google Scholar
• Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359(6):613-26
   PubMed Web of Science ®Google Scholar
• Manshouri T, Do KA, Wang X, Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101(7):2507-13
   PubMed Web of Science ®Google Scholar
• Liu AY, Robinson RR, Murray ED Jr, Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987;139(10):3521-6
   PubMed Web of Science ®Google Scholar
• Sieber T, Schoeler D, Ringel F, Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2003;121(3):458-61
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD, Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172(5):3280-8
   PubMed Web of Science ®Google Scholar
• Williams ME, Densmore JJ, Pawluczkowycz AW, Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177(10):7435-43
   PubMed Web of Science ®Google Scholar
• MabThera approved in the EU for patients with chronic lymphocytic leukaemia. Available from: http://www.roche.com/media/media_releases/med-cor-2009-02-27.htm [Last accessed 10 January 2010]
   Google Scholar
• Badoux X, Keating MJ, O'Brien SM, Long term results of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed and refractory chronic lymphocytic leukemia. Heamatologica 2009;94(s3):s3-4
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
   PubMed Web of Science ®Google Scholar
• Huhn D, von Schilling C, Wilhelm M, Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98(5):1326-31
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94(7):2217-24
   PubMed Web of Science ®Google Scholar
• Itala M, Geisler CH, Kimby E, Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69(3):129-34
   PubMed Web of Science ®Google Scholar
• Nguyen DT, Amess JA, Doughty H, IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999;62(2):76-82
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19(8):2165-70
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18(17):3135-43
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004;103(12):4416-23
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(6):1088-95
   PubMed Web of Science ®Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007:233-42
   PubMedGoogle Scholar
• Leidi M, Gotti E, Bologna L, M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J Immunol 2009;182(7):4415-22
   PubMed Web of Science ®Google Scholar
• Shibata-Koyama M, Iida S, Misaka H, Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009;37(3):309-21
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-7
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95(12):3900-8
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101(3):949-54
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-6
   PubMed Web of Science ®Google Scholar
• Golay J, Bologna L, Gotti E, Predominant complement mediated lysis of B-CLL cells by therapeutic mAbs rituximab and Campath-1H in whole blood assays. ASH Annual Meeting Proceedings. Blood 2009;114:3445
   Google Scholar
• Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48(12):673-83
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14(5):1561-70
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12(13):4027-35
   PubMed Web of Science ®Google Scholar
• Xu W, Li J, Miao K, Rituximab combining with fresh frozen plasma for the treatment of patients with refractory advanced CLL. ASH Annual Meeting Proceedings. Blood 2009;114:3450
   Google Scholar
• Klepfish A, Gilles L, Ioannis K, Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009;1173:865-73
   PubMed Web of Science ®Google Scholar
• Dalle S, Dupire S, Brunet-Manquat S, In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 2009;15(3):851-7
   PubMed Web of Science ®Google Scholar
• Treon SP, Mitsiades C, Mitsiades N, Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24(3):263-71
   Web of Science ®Google Scholar
• Macor P, Tripodo C, Zorzet S, In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67(21):10556-63
   PubMed Web of Science ®Google Scholar
• Terui Y, Mishima Y, Sugimura N, Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009;15(7):2523-30
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8
   PubMed Web of Science ®Google Scholar
• Dornan D, Spleiss O, Yeh R-FT, FC-gamma receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone. ASH Annual Meeting Proceedings. Blood 2009;114:2338
   Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103(7):2738-43
   PubMed Web of Science ®Google Scholar
• Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008;8(2):156-71
   PubMed Web of Science ®Google Scholar
• Negrea OG, Allen SL, Rai KR, Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies. ASH Annual Meeting Proceedings. Blood 2009;114:3757
   PubMedGoogle Scholar
• Cartron G. Phase I Study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia [abstract. 0495]. Haematologica 2009;94(2):201
   Google Scholar
• Morschhauser F, Carton G, Lamy T, Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. ASH Annual Meeting Proceedings. Blood 2009;114:884
   Google Scholar
• Salles G, Morschhauser F, Lamy T, A Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkins lymphoma (NHL). ASH Annual Meeting Proceedings. Blood 2009;114:1704
   Google Scholar
• Sehn LH, Assouline SE, Stewart DA, A Phase I study of GA-101 (RO5072759) monotherapy followed by maintenance in patients with multiple relapsed/refractory CD20+ malignant disease. ASH Annual Meeting Proceedings. Blood 2009;114:934
   PubMedGoogle Scholar
• Beers SA, Chan CH, James S, Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008;112(10):4170-7
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177(1):362-71
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104(6):1793-800
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181(1):822-32
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183(1):749-58
   PubMed Web of Science ®Google Scholar
• Craigen JL, Mackus WJM, Engleberts P, Ofatumumab, a human mAb targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC. ASH Annual Meeting Proceedings. Blood 2009;114: abstract 1725
   Google Scholar
• Almasri NM, Duque RE, Iturraspe J, Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40(4):259-63
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140(3):303-12
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 2008;111(12):5486-95
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66(6):791-820
   PubMed Web of Science ®Google Scholar
• Coiffier B, Tilly H, Pedersen L, Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood 2006;108:2842
   Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111(3):1094-100
   PubMed Web of Science ®Google Scholar
• Wierda W, Kipps T, Mayer J, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010 (In press)
   Web of Science ®Google Scholar
• Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94(7):2033-9
   PubMed Web of Science ®Google Scholar
• Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1(11):710-9
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Dürig J, Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial. ASH Annual Meeting Proceedings. Blood 2009;114:1725
   PubMedGoogle Scholar
• Gao G, Liang X, Jiang J, A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol 2009 (Epub Ahead of Print)
   Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park) 2009;23(6):546-53
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Bethesda, MD: U.S. National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/results?term=ofatumumab+. [Last accessed 10 January 2010]
   Google Scholar